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Abstract 
Background: Cross-reactivity among Hymenoptera venoms is an important issue when prescribing venom immu-
notherapy (VIT). Using all venoms eliciting a positive response results in treatment excess and unjustified cost 
increase. The first in vitro method that helped to identify the really causative venom was RAST-inhibition, but in latest 
years also molecular allergy (MA) diagnostics, that detects specific sIgE to single venom allergens, was introduced. We 
compared the two methods in patients with double sensitization to Vespula spp. and Polistes spp.
Methods: Fifty-four patients with anaphylactic reactions to Hymenoptera stings and positive results to skin tests and 
sIgE measurement with whole venom from Vespula spp. and Polistes dominula were included in the study. Sera from 
all patients were analyzed by CAP-inhibition (Thermo Fisher Scientific, Uppsala, Sweden) and MA diagnostics with 
recombinant Ves v 1, Ves v 5 and Pol d 5.
Results: By the data obtained from MA technique, VIT would have been prescribed to 7 patients for Polistes, to 6 
for Vespula, and to 41 for both venoms. With the data from CAP inhibition, it would have been a prescription to 15 
patients for Polistes, to 28 for Vespula, and to 11 for both venoms. A good concordance between the results of MA and 
CAP-inhibition was found only when the value in kU/l of Ves v 5 were about twice those of Pol d 5, and vice versa.
Conclusions: These findings suggest that in the choice of the venom to be used for VIT CAP-inhibition remains a piv-
otal tool, because the significance of in vitro inhibition is definite and provides a diagnostic importance higher than 
MA in patients with positive tests to both Vespula and Polistes spp.
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Background
Stings by Hymenoptera, including honeybees (Apis mel-
lifera), yellow jackets (Vespula species), paper wasps 
(Polistes species), and hornets (Dolicho vespula, Vespa 
crabro) cause systemic allergic reactions in 1–5 % of the 
population in Europe and North America [1]. The mech-
anism of these reactions is an IgE-mediated sensitiza-
tion to proteins of the venoms injected with the stings, 
particularly enzymes like phospholipase A and hyaluro-
nidase, and for vespids antigen 5 [2]. A common issue in 
diagnosis of Hymenoptera venom allergy (HVA) is the 
occurrence of multiple positive results to the different 
venoms, mainly due to cross-reactivity between phos-
pholipase A1 for vespids, and hyaluronidase, that may 
concern all venoms; another important cross-reactivity 
source is common cross-reactive carbohydrate deter-
minants (CCD) [3]. This has led to perform very often 
venom immunotherapy (VIT) with all venoms elicit-
ing a positive response to tests. However, in the 1990s 
Hamilton et al. demonstrated by the technique of RAST-
inhibition that one third of 305 patients with HVA with 
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positive Vespula- and Polistes-reactive IgE in the skin 
and/or serum were identified as candidates for exclu-
sion of Polistes from immunotherapy because their IgE 
anti-Polistes was more than 95  % cross-inhibitable with 
Vespula venom [4]. After the demonstration that CAP 
system had better performances than RAST [5], CAP-
inhibition was used instead to assess cross-reactivity. 
Concerning Hymenoptera venom, CAP-inhibition stud-
ies allowed to detect the importance of CCD as a cause 
for the double positivity to A. mellifera and Vespula 
venom [6], and the extent of cross-reactivity between 
Vespa crabro and Vespula venom [7]. Two studies 
focused the role of CAP-inhibition in suggesting the cor-
rect choice of the venom to be used for VIT in patients 
with apparent poly-sensitization [8, 9].
In the latest decade, the technique of molecular allergy 
(MA), that makes possible to measure specific IgE (sIgE) 
to single venom allergens was introduced as a further 
in  vitro method to identify with precision the causative 
venom [10]. In fact, in patients with positive tests to A. 
mellifera and Vespula venom the detection of sIgE to Api 
m 1, Ves v 1 and Ves v 5 allowed recognition of double 
sensitization from cross-reactions [11]. Indeed, double 
positivity to tests with Vespula and Polistes species is very 
frequent. In 2012, a MA-based study on patients with 
such kind of sensitization found that Polistes and Vespula 
were the culprit insect in 49 and 20 %, respectively [12], 
but this was in contrast with the general knowledge on 
the importance of these species in HVA [13].
The aim of this study was to compare the capacity of 
MA technique and CAP-inhibition to identify the culprit 
vespid in patients positive to both Vespula and Polistes 
whole venoms.
Methods
Fifty-four outpatients with anaphylactic reactions to 
Hymenoptera stings of at least Mueller grade II [14] in 
the last 6  months and double positive response to tests 
with Vespula and Polistes spp. were included in the study. 
All patients did not recognize the culprit insect and thus 
were unable to provide data to identify the really causa-
tive species. Skin tests were performed with Vespula spp. 
and Polistes dominula venom (ALK-Abellò Horsholm, 
Denmark) for Vespula species and P. dominula, with an 
initial prick test at 100 mcg/ml, followed, if negative, by 
intradermal testing at 0.1 and 1 mcg/ml [15]. Venom-spe-
cific serum IgE measurement was done by CAP system 
(Thermo Fisher Scientific, Uppsala, Sweden) to whole 
venom of Vespula spp. and P. dominula, as well to recom-
binant Ves v 1, Ves v 5 and Pol d 5.
All patients sample sera were analyzed by CAP-inhi-
bition to identify the actual sensitization by the labora-
tory method previously described by Caruso et  al. [9]. 
Briefly, two 100 mcL aliquots of patient’s serum were 
incubated separately for 12  h at 4  °C with 200  ml of P. 
dominula or Vespula venoms at increasing dilutions (0; 
25 mcg; 50 mcg; 100 mcg/ml). Subsequently, sIgE against 
each of the venoms were determined in the samples 
prepared as above. The extent of homologous (block-
age of venom-sIgE by the same venom) and heterolo-
gous (blockage of the venom-sIgE by the other venom) 
inhibition was computed with the following formula:  % 
inhibition = 100 −  [IgE inhibited sample (kU/l) × 100/
IgE anti-venom (kU/l) at zero concentration of venom]. 
According to Straumann et al. [8] a percentage of homol-
ogous inhibition >70  % was required to perform heter-
ologous inhibition. The same percentage was considered 
suggestive of cross-reactivity among Vespula and Polistes 
venom. The venom preparations tested were the same 
used for skin tests. For statistical analysis was used the 
Cohen (k) concordance index, that establishes the grade 
of concordance based on the following k values: <0, no 
concordance, 0–0.4 poor concordance, 0.4–0.6, fair con-
cordance, 0.6–0.8, good concordance, and 0.8–1, excel-
lent concordance.
All patients gave their consent to the use of the data 
obtained from the diagnostic procedures for scientific 
research.
Results
The patients had similar reactivity by skin testing to 
Vespula and Polistes spp. venom. An homologous inhi-
bition higher than 70 % was detected in all sera. Table 1 
shows the data obtained from measurement of sIgE 
to whole venom by CAP and to single allergens by MA 
technique. By such data, based on MA results VIT would 
have been prescribed to 7 patients with Polistes, to 6 
patients with Vespula, and to 41 patients with both ven-
oms. Based on CAP inhibition data VIT would have pre-
scribed to 15 patients with Polistes, to 28 patients with 
Vespula, and to 11 patients with both venoms. The con-
cordance between the results of MA with Ves v 1, Ves v 5, 
Pol d 5 and the results of CAP-inhibition was very poor, 
showing a value of k  =  0.01. A good concordance was 
found only when the value in kU/l of Ves v 5 were about 
twice those of Pol d 5, and vice versa.
Discussion
A number of studies demonstrated that VIT prevents any 
kind of reaction to insect stings in most patients and is 
completely effective in preventing fatal reactions [16]. 
To expect the same outcome in the daily practice, the 
allergist must choice the appropriate venom for VIT, but 
this is often complicated by the issue of cross-reactivity, 
which concerns all venoms but is particularly common 
for vespids [13]. The first in vitro technique that helped 
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to identify the really causative venom was RAST-inhibi-
tion, followed by CAP-inhibition, whose reagents allow 
more accurate measurements [5–8]. In recent years the 
technique of MA diagnostics was introduced and detects 
the IgE antibodies to single molecules contained in aller-
gen sources [17]. Assessing sIgE to recombinant and 
natural venom components from each vespid species in 
45 patients with allergic reactions to stings and positive 
ImmunoCAP and/or intradermal tests to vespid venoms, 
Monsalve et al. found that 9 of these patients had clearly 
higher IgE values to nVes v 1 or nVes v 5 or both, thus 
indicating that Vespula was most probably the sensitiz-
ing species for these patients, while the probable sensiti-
zation could be clearly assigned to P. dominula in 22/45 
cases, because of the higher values of Pol d 1 and/or Pol 
d 5. In 14/45, the quantitative response did not allow to 
identify the possible sensitizing species [12]. For such 
cases, the authors suggested that, “unless complex inhi-
bition studies or sting challenges are performed”, double 
sensitization should be considered to prescribe a cor-
rect immunotherapy. More recently, Hemmer stated 
that “The identification of the primary venom in patients 
testing positive for Vespula and Polistes (paper wasps) is 
particularly important in Mediterranean areas. MA tech-
nique with the marker allergens Ves v 5 and Pol d 5 may 
directly identify the causative venom in the majority of 
patients” [18].
Actually, our findings show that MA would have indi-
cated 7 treatments with Polistes and 6 with Vespula, 
while information obtained by CAP-inhibition would 
have indicated 15 treatments with Polistes and 28 with 
Vespula, thus reducing the number of double treatments 
from 41 to 11, and confirming the observation from 
Hamilton et al. on the capacity of this in vitro method to 
avoid unnecessary VIT treatments [4]. This suggests that 
in the choice of the venom to be used in immunotherapy 
CAP-inhibition remains a pivotal tool, because the sig-
nificance of in vitro inhibition is definite and provides a 
diagnostic importance higher than MA in patients with 
positive tests to both Vespula and Polistes spp. who failed 
to recognize the culprit vespid. The availability of addi-
tional molecules, such as Pol d 1, will probably improve 
the ability of MA in vespid allergy, but this warrants to 
be demonstrated by further studies. Both MA and CAP-
inhibition studies thus far available were not tested 
against a gold standard for diagnosis of HVA. Indeed, dif-
ferently from other fields of allergy, for example with the 
double-blind placebo-controlled food challenge for the 
diagnosis of food allergy [19], no gold standard is defi-
nitely accepted for HVA. In particular, the sting challenge 
test is not recommended for vespid allergy due to the var-
iable amounts of venom injected with the sting [20]. The 
actual demonstration of the tolerance to venom induced 
by VIT is based on the outcome of field stings, but fol-
low-up studies investigating the proof of the results of 
MA or CAP-inhibition by field stings are not available.
Indeed, in times of spending review also the cost-effec-
tiveness of VIT is questioned [21]. Nobody can argue 
its life-saving role when the culprit venom is used, but 
avoiding additional treatments with unnecessary venoms, 
as obtained by CAP-inhibition, that in our study spared 
30 additional treatments in 54 patients, may allow to sig-
nificantly reduce the costs.
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